Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors.

Molife LR, Dean EJ, Blanco-Codesido M, Krebs MG, Brunetto AT, Greystoke AP, Daniele G, Lee L, Kuznetsov G, Myint KT, Wood K, de Las Heras B, Ranson MR.

Clin Cancer Res. 2014 Dec 15;20(24):6284-94. doi: 10.1158/1078-0432.CCR-14-0409. Epub 2014 Oct 2.

2.

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ, Hughes G, Rahi A, Jacobs VN, Red Brewer M, Ichihara E, Sun J, Jin H, Ballard P, Al-Kadhimi K, Rowlinson R, Klinowska T, Richmond GH, Cantarini M, Kim DW, Ranson MR, Pao W.

Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.

3.

Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, Chu Q, Giaccone G, Khaira D, Ramalingam SS, Ranson MR, Dive C, McKeegan EM, Chyla BJ, Dowell BL, Chakravartty A, Nolan CE, Rudersdorf N, Busman TA, Mabry MH, Krivoshik AP, Humerickhouse RA, Shapiro GI, Gandhi L.

Clin Cancer Res. 2012 Jun 1;18(11):3163-9. doi: 10.1158/1078-0432.CCR-11-3090. Epub 2012 Apr 11.

4.

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

Rosell R, Robinet G, Szczesna A, Ramlau R, Constenla M, Mennecier BC, Pfeifer W, O'Byrne KJ, Welte T, Kolb R, Pirker R, Chemaissani A, Perol M, Ranson MR, Ellis PA, Pilz K, Reck M.

Ann Oncol. 2008 Feb;19(2):362-9. Epub 2007 Oct 17.

PMID:
17947225
5.

Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer.

Ranson MR, Cheeseman S, White S, Margison J.

Crit Rev Oncol Hematol. 2001 Feb;37(2):115-20. Review.

PMID:
11166584
6.

Management of elderly patients with lung cancer.

Ranson MR, White S, Thatcher N.

Curr Oncol Rep. 2000 Jan;2(1):90-5. Review.

PMID:
11122829
7.

Cerebral metastases in malignant mesothelioma: a case report.

Cheeseman SL, Ranson MR.

Eur J Cancer Care (Engl). 1999 Jun;8(2):104-6.

PMID:
10476113
8.

Central venous catheter placement: extending the role of the nurse.

Fitzsimmons CL, Gilleece MH, Ranson MR, Wardley A, Morris C, Scarffe JH.

J R Coll Physicians Lond. 1997 Sep-Oct;31(5):533-5.

9.

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial.

Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A.

J Clin Oncol. 1997 Oct;15(10):3185-91.

PMID:
9336354
10.

Single-agent paclitaxel in advanced non-small cell lung cancer: single-center phase II study using a 3-hour administration schedule.

Ranson MR, Jayson G, Perkins S, Anderson H, Thatcher N.

Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-6-S12-9.

PMID:
9331111
11.

Population and Bayesian pharmacokinetics in oncology.

Ranson MR, Scarffe JH.

Clin Oncol (R Coll Radiol). 1994;6(4):254-60. Review. No abstract available.

PMID:
7986764
12.

Post consolidation therapy for adult patients with acute myeloid leukaemia.

Ranson MR, Scarffe JH, Morgenstern GR, Chang J, Anderson H, Deakin DP, Oppenheim B, Heron D, Ryder D.

Br J Haematol. 1991 Oct;79(2):162-9.

PMID:
1958473
13.

An analysis of prognostic factors in stage III and IV Hodgkin's disease treated at a single centre with MVPP.

Ranson MR, Radford JA, Swindell R, Deakin DP, Wilkinson PM, Harris M, Johnson RJ, Crowther D.

Ann Oncol. 1991 Jun;2(6):423-9.

PMID:
1768629
14.

Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis.

Kamthan AG, Lind MJ, Thatcher N, Steward WP, Bronchud MH, Ranson MR, Stout R.

Eur J Cancer. 1990;26(6):691-4.

PMID:
2168191
15.

Double-blind placebo controlled study of vancomycin prophylaxis for central venous catheter insertion in cancer patients.

Ranson MR, Oppenheim BA, Jackson A, Kamthan AG, Scarffe JH.

J Hosp Infect. 1990 Jan;15(1):95-102.

PMID:
1968484

Supplemental Content

Loading ...
Support Center